Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion (FALCON)

Kanghong Pharmaceutical

Status and phase: Unknown; Phase 2

Conditions: Retinal Vein Occlusion

Treatments: Biological: Conbercept

Study type: Interventional

Funder types: Industry

Identifiers

NCT01809236

KHSWKH902008

Details and patient eligibility

About

This is a Phase II, single arm, open label clinical trial. 60 RVO patients (including 30 BRVO and 30 CRVO, respectively) are enrolled in the study. The study included a fixed treatment period (3 months) and a PRN period (6 months). In the fixed treatment period patients will receive 3 consecutive monthly intravitreal of 0.5 mg Conbercept. In the PRN period, patients are monthly visited and retreatment will be needed according to the retreatment criteria pre-specified.

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Ability and willingness to provide signed Informed Consent Form.

2. Age ≥ 18, both male and female。

3. Ocular Inclusion Criterion (Study Eye):

   • Diagnosis of Foveal center-involved macular edema due to RVO (both CRVO and BRVO) within 6 months.
   • Best corrected visual acuity (BCVA) letter score in the study eye of ≤ 73（Snellen equivalents 20/40）.
   • Central retinal thickness by OCT in the study eye ≥ 320 μm.

Exclusion criteria

1. Brisk afferent pupillary defect.
2. History of any anti-VEGF treatment in the study and/or system within 6 months before enrollment, and/or in the fellow eye within 3 month.
3. History of intraocular and/or peri-ocular corticosteroid use in the study eye within 3 months, and/or history of use steroids systemic (p.o., i.m., i.v.) within 1 month.
4. Any active infection involving the ocular including blepharitis, infectious conjunctivitis, keratitis, scleritis, endophthalmitis in either eye.
5. Any inflammatory cells detected in the anterior chamber and/or vitreous in the study eye.
6. Presence of non-RVO disease, in the opinion of the investigator, might cause macular edema, such as AMD (wet or dry), diabetes retinopathy, uveitis etc.
7. Neovascular change in the study eye and/or neovascularization of the iris or neovascular glaucoma in study eye at baseline.
8. Patients with substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by equal or more than 3 lines or medicine or surgery treatment are needed in the study eye within 4 months.
9. Patients diagnosed with systemic immune diseases and any uncontrolled clinical disease.
10. Pregnant or nursing women.
11. Patients need to exclude in the opinion of investigator.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

60 participants in 1 patient group

0.5 mg Conbercept

Experimental group

Description:

patients will receive monthly intravitreal injections of Conbercept to month 3 (total 3 times) and then on an as needed (PRN) dosing schedule based on the pre-specified retreatment criteria till to month 9.

Treatment:

Biological: Conbercept